Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

Background In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable heterozygous familial hypercholesterolemia (HeFH) or type II...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Gregory P. Geba, Kusha A. Mohammadi, Amy Damask, Charles Paulding, Luca A. Lotta, George Hindy, Robert Pordy, Garen Manvelian, Michael D. Shapiro, Vera A. Bittner, Deepak L. Bhatt, Michael Szarek, Gregory G. Schwartz, Ph. Gabriel Steg, Sergio Fazio
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-09-01
Serie:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Soggetti:	alirocumab heterozygous familial hypercholesterolemia LDL‐C type III hyperlipoproteinemia
Accesso online:	https://www.ahajournals.org/doi/10.1161/JAHA.124.041190
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!